Monday, Sanofi Said Results From GEMINI 1 And 2 Phase 3 Studies Of Tolebrutinib Did Not Meet The Primary Endpoint Of Reducing Annualized Relapse Rate, Compared To Teriflunomide, In Relapsing Forms Of Multiple Sclerosis
Portfolio Pulse from Benzinga Newsdesk
Sanofi announced that its Phase 3 studies, GEMINI 1 and 2, for Tolebrutinib did not meet the primary endpoint of reducing the annualized relapse rate in relapsing forms of multiple sclerosis compared to Teriflunomide.
September 03, 2024 | 7:47 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sanofi's Phase 3 trials for Tolebrutinib failed to meet primary endpoints, potentially impacting investor confidence and short-term stock performance.
The failure to meet primary endpoints in Phase 3 trials is a significant setback for Sanofi's Tolebrutinib, likely leading to negative investor sentiment and a potential short-term decline in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100